Latest Conference Coverage
Fosgonimeton Fails to Reach End Points, but Shows Mechanistic Potential in Alzheimer Disease
June 23rd 2022After 26 weeks of treatment, those on fosgonimeton alone without acetylcholinesterase inhibitors showed a potentially beneficial change in event-related potential P300 latency, an outcome of working memory processing speed.
The ATMRD Congress and Importance of Accessibility as a Clinician: Jill Farmer, DO, MPH
June 23rd 2022The director of the Parkinson’s Disease and Movement Disorder Program at Global Neuroscience Institute spoke about her time at the 2022 ATMRD Congress and how successful communication between patients and providers is rooted in accessibility. [WATCH TIME: 2 minutes]
The Potential of Targeting Anti-CD3 in Progressive Multiple Sclerosis: Tanuja Chitnis, MD
June 22nd 2022The associate neurologist at Brigham and Women’s Hospital provided background on a new case study of a patient with progressive MS who showed positive outcomes using foralumab, an anti-CD3 targeting agent. [WATCH TIME: 3 minutes]
Effectiveness and Promise of Glatiramer Acetate Depot in Progressive Multiple Sclerosis: Ehud Marom
June 22nd 2022The president and chief executive officer of Mapi Pharma discussed the positive phase 2 findings of a new formulation of glatiramer acetate to treat progressive forms of MS, as well as the long-term plans for the drug. [WATCH TIME: 5 minutes]
Apomorphine Sublingual Film Treatment for Parkinson Disease May Not Require Use of Antiemetics
June 20th 2022After a protocol adjustment that disallowed the use of the antiemetic trimethobenzamide during dose-titration, adverse event data from an open-label study of apomorphine sublingual film (Kynmobi; Sunovion) suggest antinausea treatment might not be necessary.
Highlights of the Advanced Therapeutics in Movement and Related Disorders Congress: Jean Hubble, MD
June 19th 2022The semi-retired neurologist and consultant with the PMD Alliance offered her takeaways from the 2022 ATMRD Congress in Washington, DC, and her advice for younger clinicians getting into the field. [WATCH TIME: 3 minutes]
The Future of Parkinson Disease Therapies and the Challenges With Stem Cell Therapies
June 19th 2022In a presentation at the 2022 ATMRD Congress, Rajesh Pahwa, MD, FANA, FAAN, spoke about the hope held for stem cell approaches and the potential to improve care with several therapies with possible approvals on the horizon.
Perspectives From a Neurology Career in Industry and Academia: Jean Hubble, MD
June 19th 2022Despite a less than favorable view of the pharmaceutical industry among the general population, there are still benefits to the work being done by clinicians who transition to this line of work according to the semi-retired neurologist and consultant with the PMD Alliance. [WATCH TIME: 2 minutes]
Physician Estimates of Needle Phobia Might Be Overstated Among Patients With Parkinson Disease
June 18th 2022A survey of more than 4000 individuals with PD and their caregivers suggests that almost 90% would be willing to use subcutaneous injectable therapies to control their disease, contrasting the current anecdotal belief of “needle phobia” in this population.
The Interdisciplinary Care Team in Movement Disorder Care: Jean Hubble, MD
June 18th 2022The semi-retired neurologist and consultant with the PMD Alliance discussed the importance of the patient care team and having multiple specialists and disciplines included in that process. [WATCH TIME: 2 minutes]
The Importance of Treatment Nuance and Novel Options in Treating Parkinson Disease
June 18th 2022In a presentation at the 2022 ATMRD Congress, Jill Farmer, DO, MPH, outlined several novel options for the treatment of OFF episodes in Parkinson disease, and stressed the need for individualized approaches to maximize patient quality of life.
Social Prescribing and Advances in Therapy for Movement Disorders: Jean Hubble, MD
June 17th 2022The semi-retired neurologist and consultant with the PMD Alliance shared her perspective on the progress that has been made in therapeutics for the treatment of movement disorders, and the role of social prescribing for these patients. [WATCH TIME: 3 minutes]
Understanding Treatment Decisions and Differences Between Diroximel Fumarate and Dimethyl Fumarate
June 16th 2022Meghan Garabedian, CRNP, MSN, nurse practitioner at the Penn Neuroscience Center, discussed her presentation at the 2022 CMSC Annual Meeting regarding the patient experience on diroximel fumarate.
Improving the Understanding of Narcolepsy and its Pathophysiology: Richard Bogan, MD, FCCP, FAASM
June 16th 2022The associate clinical professor at the University of South Carolina School of Medicine discussed the strides, but also challenges still in treating patients with narcolepsy. [WATCH TIME: 2 minutes]
The Importance of Sleep Quality for Cognitive Health Throughout the Stages of Menopause
June 15th 2022Galit L. Dunietz, PhD, MPH, assistant professor of neurology, University of Michigan, provided insight on women’s health, menopause cycles, and how sleep can have a direct impact on long-term cognitive health.
